Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Nonalcoholic fatty liver ... NASH cirrhotics, although recent evidence has suggested that NAFLD may directly promote hepatic carcinogenesis independent of cirrhosis. This review focuses on HCC ...

Type 2 diabetes (T2D) has long been established to increase the risk of liver diseases such as cirrhosis and hepatocellular carcinoma (HCC). Glucagon-like peptide 1 receptor agonists (GLP-1RAs ...

NASH is the ... can lead to cirrhosis (scarring) of the liver and the need for a liver transplant. The disease can also raise the risk of liver cancer hepatocellular carcinoma (HCC).

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients With Cirrhosis and Obesity Jan. 27, 2025 — A study shows that patients with obesity and fatty liver ...

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

Jan. 15, 2025 — Researchers have designed process that uses ultrasound to modify the behavior of cancer-fighting T cells by increasing their cell permeability. They targeted freshly isolated ...

CCL2), the primary ligand for chemokine receptor C–C chemokine receptor 2 (CCR2), is increased in livers of patients with non-alcoholic steatohepatitis (NASH) and murine models of steatohepatitis and ...

Separately, drinking damages liver cells trying to metabolize alcohol and can lead to additional fat buildup. The inflammation and scarring caused by excess fat may eventually lead to cirrhosis ...